Baird Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has maintained a Neutral rating on Intellia Therapeutics (NASDAQ:NTLA) but has lowered the price target from $24 to $18.
October 25, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Jack Allen has maintained a Neutral rating on Intellia Therapeutics but has lowered the price target from $24 to $18, indicating a less optimistic outlook.
The lowering of the price target from $24 to $18 by Baird suggests a less optimistic view on Intellia's future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100